Surya Mulukutla
Endocrinology, Diabetes & Metabolism · Edinburg, TXNPI 1568690865
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Kyowa Kirin, Inc. at 53.8% of the total. 2025 is the largest year on record at $53,865, 6.1 times the $8,836 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $699.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$105K
- Ultragenyx Pharmaceutical Inc.$71K
- Sanofi-aventis U.S. LLC$10K
- Neurocrine Biosciences, Inc.$5K
- Biomarin Pharmaceutical Inc.$3K
- Dexcom, Inc.$400
- plus $600 from 10 others
Across 55 payments — averaging $886.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$49K
What the payments were for
- Consulting fees$58,95230%
- Speaking & faculty fees$108,97056%
- Travel & lodging$21,91811%
- Food & beverage$5,0963%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 145 | $104,835 |
| Ultragenyx Pharmaceutical Inc. | 81 | $71,457 |
| Sanofi-aventis U.S. LLC | 8 | $9,879 |
| Neurocrine Biosciences, Inc. | 14 | $5,205 |
| Biomarin Pharmaceutical Inc. | 2 | $2,645 |
| Dexcom, Inc. | 9 | $400 |
| Tolmar, Inc. | 6 | $206 |
| Ascendis Pharma Endocrinology Inc | 4 | $123 |
| AstraZeneca | 1 | $90 |
| Abbott | 2 | $56 |
| Tandem Diabetes Care, Inc. | 1 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Sequel Med Tech, LLC | 1 | $23 |
| Eton Pharmaceuticals, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRYSVITA$109,794
- TZIELD$9,857
- Cryvista$9,525
- CRENESSITY$4,888
- VOXZOGO 1.2mg$2,520
- FENSOLVI$131
- DEXCOM G6 TRANSMITTER$121
How this compares
$195,021 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $197,206 |
| JardianceEmpagliflozin | 56 | $61,692 |
| TrulicityDulaglutide | 34 | $47,254 |
| MounjaroTirzepatide | 24 | $36,983 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $36,678 |
| SynjardyEmpagliflozin/Metformin Hcl | 33 | $30,491 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $22,468 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $17,849 |
| TradjentaLinagliptin | 13 | $13,213 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $10,839 |
| Novolog FlexpenInsulin Aspart | 42 | $9,303 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,372 |
| Levemir FlexpenInsulin Detemir | 20 | $4,927 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 17 | $4,441 |
| VascepaIcosapent Ethyl | 11 | $4,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $14 | $197,206132 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $28 | $84,23758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Edinburg
- Eduardo LunaEdinburg$1.3M
- Alejandro Gonzalez CamposEdinburg$185K
- Jose Llinas CepedaEdinburg$136K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.